New Indian Drug Policy Expected To Be Approved At Next Meeting
This article was originally published in PharmAsia News
India's new pharmaceutical policy is expected to be approved at its next meeting, although the date for the meeting has not been set. The Union Minister of Chemical and Fertilisers is considering a draft policy that contains some disagreements between the Chemicals Ministry and the pharmaceutical industry in India over price controls and other provisions. Under the policy as drafted so far, the list of essential medicines under price controls would increase from 74 to 354. The industry has objected to the added inclusions, arguing such a move would adversely affect research and development. (Click here for more
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.